pharmaceutical investing Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
pharmaceutical investing Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
pharmaceutical investing AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant in Head-to-Head Migraine Prevention Trial
pharmaceutical investing Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic
pharmaceutical investing AbbVie Submits Biologics License Application for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
pharmaceutical investing Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.
pharmaceutical investing U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® for Adults With Moderately to Severely Active Crohn's Disease
pharmaceutical investing AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
pharmaceutical investing Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa Evidence
pharmaceutical investing AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance for ELAHERE® in Platinum-Resistant Ovarian Cancer
pharmaceutical investing Health Canada Approves SKYRIZI® for Children Living with Moderate to Severe Plaque Psoriasis
pharmaceutical investing AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
pharmaceutical investing AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease
Premier American Uranium Completes US$5 Million Strategic Equity Investment by DISA Uranium; IsoEnergy Increases its Strategic Holding
